Datasetspublic full text
ClinicalTrials.gov
clinicaltrials · Datasets · License: Public Domain
170,442Documents
1,450Full text
2026-09-28Last indexed
Recent documents from this source
- Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation#217117
- Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants#217116
- Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)#217115
- Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above#217114
- Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali#217113
- SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults#217112
- Higher Dose Intradermal H5 Vaccine#217111
- Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children#217110
- A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety#217109
- Increasing the Uptake of Influenza and Pneumococcal Vaccines Among High-Risk Adult Patients Through GP Clinics#217108
- JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis#217107
- Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine#217106
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders#217105
- Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies#217104
- A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine#217103
- A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV#217102
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.#217101
- Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0)#217100
- Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)#217099
- A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)#217098
Source record · clinicaltrials · Datasets · License: Public Domain
Conceptio Open Knowledge Archive — counts are materialised per sync from the index (real full-text coverage, never license entitlement).